{"type":"rich","version":"1.0","title":"The BioPharm Brief: Triple Threats, TL1A Bets, and AI Brains","description":"Innovent advances a trispecific antibody into Phase 3 multiple myeloma testing, Bionyra enters the crowded TL1A race in inflammatory bowel disease, and Insilico Medicine partners with SK Biopharmaceuticals to apply AI to neuroimmune and CNS drug discovery.","author_name":"The BioPharm Brief","author_url":"https://audioboom.com/channels/5167274-the-biopharm-brief","provider_name":"Audioboom","provider_url":"https://audioboom.com","width":480,"height":95,"thumbnail_url":"https://audioboom.com/i/43709776/600x600/c","thumbnail_width":600,"thumbnail_height":600,"html":""}